SURGICAL HEMOSTATS, INTERNAL TISSUE SEALANTS, AND ADHESION BARRIERS MARKET ANALYSIS

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, By Product Type (Hemostats (Thrombin Based, Combination Hemostats, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based), Internal Tissue Sealants (Fibrin Based, Collagen Based, Protein Based, Synthetic Polymer Based), Adhesion Barriers (Film Based, Gel Based, Solution Based)), By Application (Surgical Applications (Cardiovascular Surgeries, Neurological Surgeries, Orthopedic Surgeries, Urological & Gynecological Surgeries, General Surgeries, Reconstructive, and Plastic Surgeries, Others), Trauma Cases), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2023
Code : CMI3721
Pages :171
Formats :
Excel and PDF
Industry : Medical Devices

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers MarketSize and Trends

The global surgical hemostats, internal tissue sealants, and adhesion barriers market is estimated to be valued at US$ 5,265.3 million in 2023 and is expected to exhibit a CAGR of 7.8 % during the forecast period (2023-2030).

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market: Key Trends

Strategies like fundings to expand product portfolio will drive the global surgical hemostats, internal tissue sealants, and adhesion barriers market growth, For instance, On August 31, 2021, Tissium, France based manufacturer of biodegradable sealants and adhesives for wound closure has expanded its synthetic platform to a range of indications for tissue reconstruction and treatment and for that, it has raised US$ 59 million in funding to expand into nerve, hernia repairs.

Clinical trials on newer products in field of tissue sealants and drive growth of global surgical hemostats, internal tissue sealants, and adhesion barriers market. On December 5, 2022, Salarius Pharmaceuticals, Inc., U.S. based biopharmaceutical company published preclinical data of SP-3164, an investigational small molecule protein degrader or molecular glue that showed potential for improved anti-multiple myeloma activity. It triggered the death of lab-grown cancer cells and held back cancer growth in a mouse model. Hence it may have the potential ability to treat hematological cancers.